Catridecacog

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameCatridecacog
Drug Alias NameCoagulation Factor XIII A-Subunit (Recombinant)重组卡曲得考/XIII凝血因子β亚基Recombinant factor XIII重组卡德凝血素Recombinant human factor XIII +[15] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant coagulation factor
Mechanisms of ActionFibrin modulatorsFactor XIII replacementsBlood coagulation pathway activation
TargetsFibrinogen
Therapy Area/IndicationsInflammationHemorrhageFactor XIII Deficiency +[5] 
Global Approved IndicationsFactor XIII DeficiencyBlood Coagulation Disorders, Inherited
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2012/09/03
Country/TerritoryBulgariaCanadaUnited States +[21] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesNovo Nordisk A/S
China Registration ClassN/A

Develop Information

Active CompaniesNovo Nordisk A/S
Inactive CompaniesN/A
Active IndicationsFactor XIII DeficiencyBlood Coagulation Disorders, Inherited
Inactive IndicationsInflammationHemorrhageColitis, Ulcerative

Other Information

ATC CodeB02BD11
Related LinksWikipediaDrugBankKEGG